Less is more: If AZ’s low-dose COVID-19 vaccine regimen works better, more people will benefit

Regardless of why the full-dose regimen of AstraZeneca’s COVID-19 vaccine performed worse than a partial-dose regimen, better efficacy with less vaccine means supplies will stretch farther. 

On Monday, AZD1222 from  AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and partner University of Oxford became the third COVID-19 vaccine to meet FDA’s threshold for efficacy, behind mRNA-1273 from Moderna Inc. (NASDAQ:MRNA) and BNT162b2 from Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX)...